课题基金 / 基金详情

Interdepartmental Training in Pharmacological Sciences

Interdepartmental Training in Pharmacological Sciences
药理学科学跨部门培训
批准号:
10616678
负责人:
Lori L. Isom
金额:
$63.66万
依托单位国家:
美国
项目类别:
财政年份:
2021
资助国家:
美国
项目状态:
未结题
起止时间:
2021-07-01 至 2026-06-30

项目摘要

项目成果

Lori L. Isom的其他基金

相似基金

相关文献

中文摘要
翻译
此新应用程序请求支持重新设计的密歇根大学(U-M)药理学 科学培训计划(PSTP)。PSTP的目标是发展一批训练有素的生物医学人才 具有技术、操作和专业技能的科学家在 以道德负责和严谨的态度,进入生物医学研究的不同职业 劳动力。要求每年支持12名学员(任何一年的6年制2期和6年制3期学员) 在这五年的资助中。密歇根大学PSTP是两所医学院之间的长期合作 以及药学院,提供协作性、转化性教育、研究培训和职业 为四个学位授予项目的博士前实习生开发:药理学、生物化学、 药物化学和药学。以能力为基础的新PSTP课程, 包括真实世界药物发现的体验式计划,旨在为学员提供强大的 对药理科学有基础的了解,提供严谨的培训表现 和可重复的研究,并提供职业发展、团队合作和领导力培训,所有这些都在 训练有素、敬业奉献的教师指导。广泛而成功的校友基础提供了 职业指导、网络和未来的就业机会。PSTP导师鼓励学员思考 广泛地谈论人类疾病的研究问题,同时将他们的论文研究集中在一个关键的、尚未填补的差距上 在知识上运用严谨的实验设计和方法。这一重新设计的强大、跨学科、但 个性化的药理学培训将给受训者带来明显的优势,因为他们将 能迅速找到工作,并能很好地为NIH发现新药的任务做出贡献。这个 开发新的有效的治疗剂是一项关键的、持续的全球需求,它严格要求 训练有素、富有创新精神的团队合作伙伴,能够解决医疗保健领域的关键问题。至关重要的是,美国继续 培养来自不同背景的博士级科学家,并在药理学和 了解基础科学和转化医学的实验治疗学。密歇根大学是首映式 在全球范围内研究和培训生物医学科学研究生的机构。虽然 密歇根大学在与此培训计划相关的系中有单独的研究生课程,PSTP是 密歇根大学唯一一个利用教职员工、校友、密歇根药物发现研究所、 以及这些单位的学生对促进跨学科教育、合作研究、 职业发展,以及以团队为基础的创新和目标发现和翻译方法 实验治疗学的发展。
英文摘要
This new application requests support for the newly re-designed University of Michigan (U-M) Pharmacological Sciences Training Program (PSTP). The goal of the PSTP is to develop a diverse pool of well-trained biomedical scientists who have the technical, operational and professional skills to conduct pharmacological research in an ethically responsible and rigorous manner, and to enter diverse careers in the biomedical research workforce. Annual support for 12 trainees (6-Year 2 and 6-Year 3 Trainees in any one year) is requested throughout the five years of funding. The U-M PSTP is a long-standing collaboration between the Medical School and the College of Pharmacy that provides synergistic, translational education, research training, and career development for pre-doctoral trainees in four degree-granting programs: Pharmacology, Biological Chemistry, Medicinal Chemistry, and Pharmaceutical Sciences. The new, competency-based PSTP curriculum, which includes an experiential program in Real-World Drug Discovery, is designed to provide trainees with a strong foundational understanding of the pharmacological sciences, to provide training in the performance of rigorous and reproducible research, and to provide career development, teamwork, and leadership training, all under the direction of well-trained and dedicated faculty mentors. An extensive and successful alumni base provides career mentorship, networking, and future employment opportunities. PSTP mentors encourage trainees to think broadly about research problems in human disease while focusing their thesis research on a critical, unmet gap in knowledge using rigorous experimental design and methods. This re-designed strong, interdisciplinary, yet individualized, training in the pharmacological sciences will give trainees a distinct advantage in that they will be rapidly employable and well positioned to contribute to the NIH mission to discover new medicines. The development of novel and effective therapeutic agents is a critical, on-going global need that requires rigorously trained, innovative team players to solve critical problems in health care. It is essential that the US continue to produce doctoral-level scientists from diverse backgrounds with broad training in pharmacological sciences and experimental therapeutics who understand basic science and translational medicine. U-M is a premiere institution in research and training of graduate students in the biomedical sciences on a global scale. Although U-M has individual graduate programs in the Departments associated with this training program, the PSTP is the only program at U-M that draws upon the expertise of faculty, alumni, the Michigan Drug Discovery Institute, and the enthusiasm of students across these units to fertilize interdisciplinary education, collaborative research, career development, and team-based approaches to innovation and translation in target discovery and development of experimental therapeutics.
期刊论文(17)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.jtha.2023.09.013
发表时间: 2023-12
期刊: Journal of thrombosis and haemostasis : JTH
影响因子: --
作者: [L. Stanger;Adriana Yamaguchi;M. Holinstat]
通讯作者: L. Stanger;Adriana Yamaguchi;M. Holinstat
DOI: 10.1037/pha0000425
发表时间: 2021-12
期刊: Experimental and clinical psychopharmacology
影响因子: 2.3
作者: [Altshuler RD, Mac RC, Gnegy ME, Jutkiewicz EM]
通讯作者: Jutkiewicz EM
DOI: 10.1080/19420862.2022.2146629
发表时间: 2022-01
期刊: MABS
影响因子: 5.3
作者: [Makowski, Emily K., Chen, Hongwei, Lambert, Matthew, Bennett, Eric M., Eschmann, Nicole S., Zhang, Yulei, Zupancic, Jennifer M., Desai, Alec A., Smith, Matthew D., Lou, Wenjia, Fernando, Amendra, Tully, Timothy, Gallo, Christopher J., Lin, Laura, Tessier, Peter M.]
通讯作者: Tessier, Peter M.
DOI: 10.1016/j.mce.2021.111261
发表时间: 2021-05-15
期刊: Molecular and cellular endocrinology
影响因子: 4.1
作者: [Burris-Hiday SD, Scott EE]
通讯作者: Scott EE
共 6 条
    Development and Validation of a Transgenic Rabbit Model of Dravet Syndrome
    Interdepartmental Training in Pharmacological Sciences
    Cardiac Mechanisms of Sudden Unexpected Death in Epilepsy
    Development of a Rabbit Model of SCN1A-linked Dravet Syndrome
    海外基金